目的 評(píng)價(jià)第3代表皮生長(zhǎng)因子受體（EGFR）酪氨酸激酶抑制劑（EGFR-TKI）奧希替尼治療ⅠB～ⅢA期完全切除EGFR突變的非小細(xì)胞肺癌（NSCLC）患者的成本-效果。方法 建立動(dòng)態(tài)Markov模型獲得的質(zhì)量調(diào)整生命年（QALYs）。采用成本-效果分析法，以增量成本-效果比（ICER）為指標(biāo)，評(píng)價(jià)奧希替尼用于ⅠB～ⅢA期完全切除EGFR突變的NSCLC患者輔助治療的成本-效果，并進(jìn)行敏感性分析。結(jié)果 在成本-效果分析中，與安慰劑組相比，奧希替尼組提高了0.553QALYs，治療費(fèi)用提高了150 854.42元，ICER值為273 006.87元/QALY。結(jié)論 奧希替尼在中國(guó)人群中治療ⅠB～ⅢA期完全切除EGFR突變非小細(xì)胞肺癌不存在經(jīng)濟(jì)學(xué)優(yōu)勢(shì)。

Objective To evaluate the cost-effectiveness of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), as adjuvant therapy for patients with completely resected stage IB—IIIA EGFR-mutated nonsmall cell lung cancer (NSCLC). Methods A dynamic Markov model was developed to estimate quality-adjusted life years (QALYs). Cost-effectiveness analysis was performed using the incremental cost-effectiveness ratio (ICER) as the primary indicator. Sensitivity analyses were conducted to assess the robustness of the results. Results In the cost-effectiveness analysis, compared with the placebo group, the osimertinib group provided an additional 0.553 QALYs at an incremental cost of CNY 150 854.42, resulting in an ICER of CNY 273 006.87 per QALY gained. Conclusion Osimertinib does not demonstrate economic advantages in the Chinese population for adjuvant therapy of stage IB—IIIA EGFR-mutated NSCLC.

R979.1

遼寧省科學(xué)技術(shù)計(jì)劃應(yīng)用基礎(chǔ)研究項(xiàng)目（2022JH2/101300093）